Zhejiang Wecome Pharmaceutical (300878.SZ) released its performance for the first three quarters, with a net income of 44.1 million yuan, a year-on-year decrease of 36.41%.

Zhejiang Wecome Pharmaceutical (300878.SZ) disclosed its third quarter report for 2024, achieving revenue of 3....

According to the Zhixun Finance APP, Zhejiang Wecome Pharmaceutical (300878.SZ) disclosed its third quarter report for 2024, achieving revenue of 0.371 billion yuan, a year-on-year decrease of 14.16%; net income attributable to shareholders was 44.1 million yuan, a year-on-year decrease of 36.41%; non-net profit loss was 47.41 million yuan; and basic earnings per share was 0.31 yuan.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

维康药业(300878.SZ)发布前三季度业绩，净利润4410万元，同比下降36.41%

Zhejiang Wecome Pharmaceutical (300878.SZ) released its performance for the first three quarters, with a net income of 44.1 million yuan, a year-on-year decrease of 36.41%.

Risk Disclaimer

Statement